| Benefited from Experienced Management:
The company is promoted by an experienced group comprising Mr. Rajni Babulal Mungra, Mr. Ashish Hasmukh Shah, Mr. Divyangkumar Dhanjibhai Vadi, and Ms. Hiral Ashokbhai Vadodariya. The promoters possess over a decade of experience in the same line of business, which has enabled the company to evolve from a trading and distribution entity to a manufacturer of generic medicines. Over the years the company has developed healthy relationship with its customers and suppliers. Acuite believes that going forward, BIL is expected to benefit from its experienced management team.
Continuous improvement Scale of Operation with marginal moderation in operating Profitability:
BIL has demonstrated a steady expansion in its scale of operations, with revenue increasing to Rs. 281.84 crore in FY26 (provisional) from Rs. 200.87 crore in FY25 and Rs. 163.81 crore in FY24, supported by growth in both trading and manufacturing segments, driven primarily by higher sales volumes across product categories. The revenue mix remains largely contributed by trading activities, contributing about 88% of total revenue, while the remaining 12% is derived from own manufacturing and job work operations. Further BIL has already achieved total revenue of Rs.72.20 crores in Q1FY27 as compared to Rs.64.70 crores in Q1FY26 indicates revenue growth in the medium term. Despite strong topline growth, profitability has exhibited some volatility, with EBITDA margin declining to 5.58% in FY26 (prov.) from 6.44% in FY25, mainly due to higher raw material consumption costs. However, PAT margin improved marginally to 2.70% in FY26 (prov.) from 2.15% in FY25, supported by lower finance costs. Going forward, the company expects further improvement in its operating performance, driven by increased contribution from manufacturing activities as they plan to foray into export markets with their own brand. Also the Company is planning expand their capacity by twice of the current installed capacity in FY 27, cost for the same is around Rs.5-6 crore, out of which Rs.5 crore will be funded through borrowings and remaining will be funded through internal accruals. Acuité believes that while the overall operating performance is likely to improve over the medium term, the sustainability of profitability margins will remain a key monitorable.
Moderate Financial Risk profile:
The financial risk profile of the company is marked by improvement in net worth, low gearing, and moderate debt protection metrics. The adjusted tangible net worth increased substantially to Rs. 40.26 crore in FY26 (provl) from Rs. 14.57 crore in FY25 and Rs. 10.32 crore in FY24, driven by Rs.5.22 crore of equity infusion, internal accruals, and the treatment of unsecured loans amounting to Rs. 13.12 crore as quasi-equity, as these have been subordinated to debt. Total borrowings declined to Rs. 45.64 crore in FY26 (prov.) from Rs. 51.05 crore in FY25, resulting in an improvement in gearing to 1.13 times from 3.50 times. Debt protection metrics also improved, with interest coverage ratio and debt service coverage ratio rising to 5.04 times and 1.87 times, respectively, in FY26 (prov.) from 2.63 times and 1.38 times in FY25. Further, leverage indicators such as Total Liabilities to Tangible Net Worth (TOL/TNW) and Debt/EBITDA improved to 1.49 times and 2.89 times, respectively, in FY26 (prov.) from 4.63 times and 3.91 times in FY25. Acuité believes that the company’s financial risk profile is expected to improve further over the medium term in the absence of any major debt-funded capital expenditure plans.
Efficient Working Capital Management:
The working capital management remained efficient, as reflected by GCA days of 74 days in FY26 (prov.) compared to 73 days in FY25. Inventory days improved to 52 days in FY26 (prov.) from 67 days in FY25 on account of better inventory control and stocking aligned with customer demand, while the company generally maintains inventory in the range of 45–60 days. Debtor days stood at 19 days in FY26 (prov.), pertain largely to the manufacturing segment, and the same is in line with the average collection period of 15–20 days. Creditor days also improved to 13 days in FY26 (prov.) from 28 days in FY25. Overall, Acuite believes the working capital management to remain moderate over the medium term, considering the inherent nature of the company’s operations.
|
| Susceptibility to fluctuations in raw-material prices, intense competition, and regulatory risks:
The entity operates in both trading as well as manufacturing segments. Margins in the trading segment remain constrained due to elevated procurement costs, including volatility in input prices coupled with limited pricing flexibility amid intense competition and regulatory price caps. The manufacturing segment, though relatively less for the company, still is impacted by fluctuations in key raw material costs i.e APIs (Active Pharmaceutical Ingredients) and pricing pressures in a competitive landscape. Overall, these factors continue to exert pressure on profitability and limit margin expansion.
|
